The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare diseases, among others.

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...

Ann Robinson reviews the latest research Postpartum haemorrhage kills around 70 000 women a year. Since the results of the WOMAN trial in 2017, intravenous tranexamic acid given within three hours of ...

BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based ...